Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension
Irbesartan, an angiotensin II receptor blocker (ARB), acts as a selective PPAR-γ (peroxisome proliferator-activated receptor-γ) modulator, and thus may have anti-inflammatory and antioxidative effects, as well as beneficial effects on glucose and lipid metabolism. We enrolled 118 high-risk hypertensive outpatients, defined as those with the presence of at least one complication such as coronary artery disease, cerebrovascular disease or diabetes, and who were receiving any ARB except for irbesartan (67±10 years, 80% male subjects). After a 4-week control period, all ARBs were switched to an equivalent dose of irbesartan. We evaluated changes in lipid parameters, inflammatory markers and derivatives of reactive oxygen metabolites (d-ROMs) as an oxidative stress index. After 12 weeks of irbesartan, there were significant decreases in triglycerides (138±73 versus 123±65 mg dl(-1), P<0.05), high-sensitivity C-reactive protein (hs-CRP) (2.80±0.53 versus 2.66±0.50, log (ng ml(-1)), P<0.05) and d-ROMs (338±74 versus 305±62 U.CARR, P<0.001). There were significant increases in high-density lipoprotein cholesterol (50±13 versus 52±14 mg dl(-1), P<0.01) and adiponectin (9.4±6.2 versus 16.6±13.4 ng ml(-1), P<0.05). There were no significant changes in systolic and diastolic blood pressure. The change in d-ROMs from baseline to 12 weeks was positively correlated with the change in hs-CRP (R=0.34, P<0.01). Irbesartan appears to exert beneficial effects on oxidative stress, inflammation, lipid metabolism and metabolic syndrome, indicating that it may be useful in high-risk hypertensive patients.
| Errataetall: |
CommentIn: Hypertens Res. 2013 Jul;36(7):586-7. - PMID 23575385 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - 36(2013), 7 vom: 15. Juli, Seite 608-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taguchi, Isao [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.04.2014 Date Revised 17.03.2022 published: Print-Electronic CommentIn: Hypertens Res. 2013 Jul;36(7):586-7. - PMID 23575385 Citation Status MEDLINE |
|---|
| doi: |
10.1038/hr.2013.3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM22518270X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM22518270X | ||
| 003 | DE-627 | ||
| 005 | 20231224064554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/hr.2013.3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0750.xml |
| 035 | |a (DE-627)NLM22518270X | ||
| 035 | |a (NLM)23425956 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taguchi, Isao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2014 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hypertens Res. 2013 Jul;36(7):586-7. - PMID 23575385 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Irbesartan, an angiotensin II receptor blocker (ARB), acts as a selective PPAR-γ (peroxisome proliferator-activated receptor-γ) modulator, and thus may have anti-inflammatory and antioxidative effects, as well as beneficial effects on glucose and lipid metabolism. We enrolled 118 high-risk hypertensive outpatients, defined as those with the presence of at least one complication such as coronary artery disease, cerebrovascular disease or diabetes, and who were receiving any ARB except for irbesartan (67±10 years, 80% male subjects). After a 4-week control period, all ARBs were switched to an equivalent dose of irbesartan. We evaluated changes in lipid parameters, inflammatory markers and derivatives of reactive oxygen metabolites (d-ROMs) as an oxidative stress index. After 12 weeks of irbesartan, there were significant decreases in triglycerides (138±73 versus 123±65 mg dl(-1), P<0.05), high-sensitivity C-reactive protein (hs-CRP) (2.80±0.53 versus 2.66±0.50, log (ng ml(-1)), P<0.05) and d-ROMs (338±74 versus 305±62 U.CARR, P<0.001). There were significant increases in high-density lipoprotein cholesterol (50±13 versus 52±14 mg dl(-1), P<0.01) and adiponectin (9.4±6.2 versus 16.6±13.4 ng ml(-1), P<0.05). There were no significant changes in systolic and diastolic blood pressure. The change in d-ROMs from baseline to 12 weeks was positively correlated with the change in hs-CRP (R=0.34, P<0.01). Irbesartan appears to exert beneficial effects on oxidative stress, inflammation, lipid metabolism and metabolic syndrome, indicating that it may be useful in high-risk hypertensive patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Biphenyl Compounds |2 NLM | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 650 | 7 | |a PPAR gamma |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Irbesartan |2 NLM | |
| 650 | 7 | |a J0E2756Z7N |2 NLM | |
| 700 | 1 | |a Toyoda, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Arikawa, Takuo |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Migaku |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Mikie |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Shichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Node, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Teruo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g 36(2013), 7 vom: 15. Juli, Seite 608-13 |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2013 |g number:7 |g day:15 |g month:07 |g pages:608-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/hr.2013.3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2013 |e 7 |b 15 |c 07 |h 608-13 | ||